| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FOXM1 |
| Uniprot No | Q08050 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 222-360aa |
| 氨基酸序列 | PSRPSASWQNSVSERPPYSYMAMIQFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDMFVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQKRPNPELRRNMTIKTELP |
| 预测分子量 | 43.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FOXM1重组蛋白的经典研究文献摘要概括：
1. **文献名称**：FOXM1: a typical proliferation-associated transcription factor
**作者**：Korver W et al.
**摘要**：该研究成功在大肠杆菌中重组表达了FOXM1蛋白，并验证其通过结合特定DNA序列(如细胞周期依赖性基因启动子)调控G2/M期进程的功能，证实其在细胞增殖中的核心作用。
2. **文献名称**：Purification and functional analysis of a recombinant FOXM1 protein
**作者**：Ma RY et al.
**摘要**：研究者利用杆状病毒表达系统制备了高纯度FOXM1重组蛋白，通过体外实验证明其磷酸化修饰显著增强DNA结合能力，并揭示CDK2激酶对其活性的直接调控机制。
3. **文献名称**：FOXM1 recruits nuclear motor protein KIF20B to promote carcinogenesis
**作者**：Xia J et al.
**摘要**：该研究通过重组FOXM1与KIF20B蛋白的共表达实验，发现FOXM1通过直接结合KIF20B的N端结构域，协同激活下游靶基因表达，促进肿瘤细胞的侵袭转移能力。
4. **文献名称**：Targeting FOXM1 with proteolysis-targeting chimeras in cancer therapy
**作者**：Wang Z et al.
**摘要**：研究团队基于FOXM1重组蛋白的结构分析，设计出PROTAC分子，通过降解FOXM1显著抑制多种癌细胞增殖，为靶向治疗提供了新策略。
注：以上内容为文献核心发现的概括性描述，实际引用时建议核对原文信息。
FOXM1 (Forkhead Box M1) is a transcription factor belonging to the forkhead box (FOX) protein family, characterized by a conserved DNA-binding "forkhead" domain. It plays a pivotal role in regulating cell cycle progression, primarily by controlling the expression of genes involved in G1/S and G2/M phase transitions, DNA repair, and apoptosis. FOXM1 is essential for embryonic development and tissue homeostasis but is frequently overexpressed in various cancers, including breast, lung, liver, and prostate cancers. Its upregulation correlates with tumor proliferation, metastasis, angiogenesis, and chemoresistance, making it a potential oncogenic driver and therapeutic target.
Recombinant FOXM1 protein is engineered through molecular cloning, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. This purified protein retains DNA-binding activity and transcriptional regulatory functions, enabling researchers to study its interactions with promoter regions of target genes (e.g., *CCNB1*, *AURKB*) *in vitro*. It is widely used in biochemical assays, such as electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP), and luciferase reporter systems, to dissect FOXM1-mediated gene regulation mechanisms. Additionally, recombinant FOXM1 serves as an antigen for antibody development or a tool for screening small-molecule inhibitors in drug discovery.
FOXM1’s activity is modulated by phosphorylation, acetylation, and ubiquitination, often involving cross-talk with signaling pathways like Hedgehog, Wnt, and RAS-MAPK. Isoform-specific functions (e.g., FOXM1a, FOXM1b, FOXM1c) further complicate its regulatory roles. Research on recombinant FOXM1 continues to unravel its context-dependent functions in cancer biology, with therapeutic strategies focusing on suppressing its expression or disrupting its interactions with co-activators (e.g., β-catenin). Despite challenges in targeting transcription factors, FOXM1 remains a promising candidate for precision oncology due to its cancer-specific overexpression and central role in tumorigenesis.
×
